16089-70-6Relevant articles and documents
Cooperative Multifunctional Catalysts for Nitrone Synthesis: Platinum Nanoclusters in Amine-Functionalized Metal–Organic Frameworks
Li, Xinle,Zhang, Biying,Tang, Linlin,Goh, Tian Wei,Qi, Shuyan,Volkov, Alexander,Pei, Yuchen,Qi, Zhiyuan,Tsung, Chia-Kuang,Stanley, Levi,Huang, Wenyu
supporting information, p. 16371 - 16375 (2017/11/28)
Nitrones are key intermediates in organic synthesis and the pharmaceutical industry. The heterogeneous synthesis of nitrones with multifunctional catalysts is extremely attractive but rarely explored. Herein, we report ultrasmall platinum nanoclusters (PtNCs) encapsulated in amine-functionalized Zr metal–organic framework (MOF), UiO-66-NH2 (Pt@UiO-66-NH2) as a multifunctional catalyst in the one-pot tandem synthesis of nitrones. By virtue of the cooperative interplay among the selective hydrogenation activity provided by the ultrasmall PtNCs and Lewis acidity/basicity/nanoconfinement endowed by UiO-66-NH2, Pt@UiO-66-NH2 exhibits remarkable activity and selectivity, in comparison to Pt/carbon, Pt@UiO-66, and Pd@UiO-66-NH2. Pt@UiO-66-NH2 also outperforms Pt nanoparticles supported on the external surface of the same MOF (Pt/UiO-66-NH2). To our knowledge, this work demonstrates the first examples of one-pot synthesis of nitrones using recyclable multifunctional heterogeneous catalysts.
Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
-
, (2008/06/13)
The present invention relates generally to cyclic carbamates and isoxazolidines or Formula (I) or their pharmaceutically acceptable salts thereof, which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharma
Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines
Confalone, Pat N.,Fuqiang, Jin,Mousa, Shaker A.
, p. 55 - 58 (2007/10/03)
A series of isoxazolidines has been synthesized as mimetics of the RGD sequence and was evaluated as antagonists of the platelet glycoprotein IIb/IIIa receptor. These compounds were shown to be highly potent GPIIb/IIIa antagonists, exhibiting submicromolar potencies.